Gilead Sciences, Inc. (GILD)
| Previous close | 63.23 |
| Open | 63.42 |
| Bid | 64.85 x 900 |
| Ask | 64.90 x 1100 |
| Day's range | 63.30 - 64.75 |
| 52-week range | 56.56 - 85.97 |
| Volume | 9,761,404 |
| Avg. volume | 9,124,683 |
| Market cap | 81.201B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 659.39 |
| EPS (TTM) | 0.10 |
| Earnings date | 28 Apr 2021 - 03 May 2021 |
| Forward dividend & yield | 2.84 (4.39%) |
| Ex-dividend date | 12 Mar 2021 |
| 1y target est | 74.54 |
- Zacks
Why Is Gilead (GILD) Down 1.8% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool
After 2 Licensing Deals Will GlaxoSmithKline Acquire Vir?
Vir Biotechnolgy (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) recently expanded their partnership from a single drug to treat COVID-19 to a multi-drug partnership that covers a drug for the flu, as well as drugs that Vir hasn't even developed yet.
- Business Wire
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults. The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2021).
